Key facts
- Rege Nephro’s last known valuation is $36.4M.
- It has raised $34.8M; the latest was Later Stage VC ($17.4M) in Oct 2024.
- Notable investors include Mitsubishi UFJ Capital, Global Brain, SMBC Venture Capital, J-Startup, JIC Venture Growth Investments — 33 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 33 names
- ·Watchlist + deal alerts for Rege Nephro
- ·The full record, as it builds
Funding rounds
No funding rounds for Rege Nephro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rege Nephro
Developer of therapeutic drugs designed for patients suffering from renal failure. The company's drugs use core seed technology, pluripotent stem cells that produce erythropoietin (EPO), ureteral blast cells, and surface markers specific to nephron progenitor cells, enabling doctors to reduce the number of patients who shift to dialysis as much as possible.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2019
- Employees
- 12
- Website
- regenephro.co.jp/
- Ownership
- Privately Held (backing)
Rege Nephro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rege Nephro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rege Nephro in its N-PORT filings yet. We sweep new filings monthly.